Narrative review / 2021
A commentary notes clinical evidence that an NAD+ booster increases muscle insulin sensitivity in postmenopausal prediabetic women.
This commentary highlights findings from Yoshino et al. (2021) regarding NAD+ boosters. The authors note that clinical evidence demonstrates an NAD+ booster increases muscle insulin sensitivity in postmenopausal prediabetic women. This validates the therapeutic potential of NAD+ boosters in humans for addressing metabolic disorders associated with aging and obesity.
- Study type
- Commentary on clinical evidence
- Who was studied
- Postmenopausal prediabetic women
- What was measured
- Muscle insulin sensitivity
THE PAPER
The therapeutic promises of NAD+ boosters.
Montllor-Albalate C, Song Z, Chen D. Cell Metab, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.